Drug Profile
Research programme: chemokine receptor modulators - Affitech A/S
Alternative Names: AT 007 - Affitech; AT 008 - Affitech; AT 009; AT 010; AT007; AT008; AT008/CCR4Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Affitech A/S
- Class Antibodies; Antineoplastics
- Mechanism of Action CCR4 receptor antagonists; Chemokine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Lymphoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Denmark (Parenteral)